Stem Cell Therapy for Cerebral Palsy

Phase 1WithdrawnNCT01978821

Neurogen Brain and Spine Institute

Overview

the purpose of this study was to study the effect of stem cell therapy on common symptoms of cerebral palsy patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Cerebral Palsy

Interventions

Autologous bone marrow mononuclear cell transplantationPROCEDURE

Eligibility

Sex: ALLMin age: 17 MonthsMax age: 22 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed cases of any type of Cerebral Palsy * age above 12 months. Exclusion Criteria: * presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus * malignancies * bleeding tendencies * pneumonia * renal failure * severe liver dysfunction * severe anemia \[Hemoglobin \< 8\] * any bone marrow disorder * space occupying lesion in brain * other acute medical conditions such as respiratory infection and pyrexia.

Locations (1)

Neurogen brain and spine institute

Mumbai, Maharashtra, India

Outcomes

Primary Outcomes

Change in clinical symptoms of cerebral palsy after 6 months

Time frame: Six months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.